Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 4, 2014, Pages 892-898

  Gan, Gregory N ^a   Weickhardt, Andrew J ^b   Scheier, Benjamin ^b   Doebele, Robert C ^b   Gaspar, Laurie E ^a   Kavanagh, Brian D ^a   Camidge, D Ross ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATIVE THERAPY; DISEASE PROGRESSION; DOSE RESPONSE RELATIONSHIPS; EQUIVALENT DOSE; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; OVERALL SURVIVAL RATES;

BIOLOGICAL ORGANS; DISEASES; ENZYMES; NEUROPHYSIOLOGY; ONCOLOGY; RADIOTHERAPY; TOXICITY;

DISEASE CONTROL;

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABLATION THERAPY; ADULT; AGED; ANOREXIA; ARM EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXTRA CENTRAL NERVOUS SYSTEM TUMOR; FATIGUE; FEMALE; HUMAN; LOCAL ABLATIVE THERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; RADIOSURGERY; RASH; SHOULDER PAIN; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE; YOUNG ADULT;

EID: 84896737519     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.11.010     Document Type: Article

References (24)

1. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
2. D. Kim, M. Ahn, and Y. Shi et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer J Clin Oncol 30 2012 7533
3. E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
4. G.J. Riely, T.L. Evans, and R. Salgia et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) J Thorac Oncol 7 2012 S204
5. R.C. Doebele, A.B. Pilling, and D.L. Aisner et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
6. R. Katayama, A.T. Shaw, and T.M. Khan et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 2012 120ra17
7. D.R. Camidge, Y.J. Bang, and E.L. Kwak et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
8. D. Camidge, Y. Bang, and E. Kwak et al. Progression-free survival from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer J Clin Oncol 29 2011 2501
9. A.J. Weickhardt, B. Scheier, and J.M. Burke et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
10. K.E. Rusthoven, B.D. Kavanagh, and S.H. Burri et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases J Clin Oncol 27 2009 1579 1584
11. K.E. Rusthoven, B.D. Kavanagh, and H. Cardenes et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases J Clin Oncol 27 2009 1572 1578
12. C. Park, L. Papiez, and S. Zhang et al. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy Int J Radiat Oncol Biol Phys 70 2008 847 852
13. Y. Fong, J. Fortner, and R.L. Sun et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases Ann Surg 230 1999 309 318 discussion 318-321
14. K.S. Hughes, R. Simon, and S. Songhorabodi et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence Surgery 100 1986 278 284
15. B. Nordlinger, M. Guiguet, and J.C. Vaillant et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77 1996 1254 1262
16. M.A. Stinauer, B.D. Kavanagh, and T.E. Schefter et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control Radiat Oncol 6 2011 34
17. A.T. Shaw, B.Y. Yeap, and B.J. Solomon et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis Lancet Oncol 12 2011 1004 1012
18. H. Onishi, H. Shirato, and Y. Nagata et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2 7 Suppl. 3 2007 S94 S100
19. Shaw AT, Kim DW, Nakagawa K, et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). Presented at the European Society for Medical Oncology 37th Annual Meeting, September 28 -October 2, 2012, Vienna, Austria.
20. D.B. Costa, S. Kobayashi, and S.S. Pandya et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J Clin Oncol 29 2011 e443 e445
21. H.A. Yu, C.S. Sima, and J. Huang et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 8 2013 346 351
22. V.A. Miller, V. Hirsh, and J. Cadranel et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
23. E.T. Browning, A.J. Weickhardt, and D.R. Camidge Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer J Thorac Oncol 8 2013 e21
24. P. Lee, J.G. Bazan, and P.W. Lavori et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer Clin Lung Cancer 13 2012 52 58